Stockscreener 앱 받기
18.10
1.17%
0.21
시장 영업 전:
18.06
-0.04
-0.22%
Novocure Ltd 주식(NVCR)의 최신 뉴스
A Look At NovoCure (NVCR) Valuation After Raised 2026 Revenue Guidance And Q1 Beat - simplywall.st
Soleus discloses 10.49M-share stake in NovoCure (NASDAQ: NVCR) - Stock Titan
Oncology Company Given Neutral Rating as Q1/26 Beat Sets Up Catalyst - Streetwise Reports
NovoCure Ltd (MEX:NVCRN) Stock Price & 30 Year Financial Data - GuruFocus
NovoCure Ltd (MEX:NVCRN) DCF Valuation - GuruFocus
NovoCure Ltd (MEX:NVCRN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
NovoCure Ltd (MEX:NVCRN) Stock Earnings Transcripts - GuruFocus
Oncology Co. Tests Advanced Cancer Treatments, Reports Q1 2026 Financial Results - Streetwise Reports
MSN Money - MSN
Why NovoCure (NVCR) Is Up 33.2% After FDA Clears Optune Pax And Guidance Ticks Higher - Sahm
International Markets and NovoCure (NVCR): A Deep Dive for Investors - Yahoo Finance
Wells Fargo Maintains Novocure(NVCR.US) With Hold Rating, Raises Target Price to $17 - Moomoo
NovoCure’s Optune Pax Win And TRIDENT Data Shape Growth Outlook - Sahm
NovoCure Limited Surges As Guidance Hike Fuels NVCR Rally - timothysykes.com
Here's What Analysts Are Forecasting For NovoCure Limited (NASDAQ:NVCR) After Its First-Quarter Results - Moomoo
NovoCure Limited (NASDAQ:NVCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
NovoCure Ltd (NVCR) Shares Surge 9.3% -- What GF Score of 70 Tel - GuruFocus
NovoCure Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm
NovoCure (NASDAQ:NVCR) Trading 6.8% HigherShould You Buy? - MarketBeat
NVCR Maintained by Evercore ISI Group -- Price Target Raised to $20 - GuruFocus
Evercore Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $20 - Moomoo
NovoCure Ltd (NVCR) Q1 2026 Earnings Call Highlights: Revenue Gr - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
NovoCure Limited (NASDAQ:NVCR) Q1 2026 Earnings Call Transcript - Insider Monkey
NovoCure (NVCR) Earnings Story Centers On 20.6% Revenue Growth Versus Ongoing Losses - simplywall.st
NovoCure Earnings Call Highlights Growth, One-Time Hit - TipRanks
NovoCure Limited Q1 2026 Earnings Call Summary - Yahoo Finance
NovoCure (NASDAQ:NVCR) Announces Earnings Results - MarketBeat
NovoCure Ltd Q1 2026 Financial Results: Revenues, Losses, and Key Forward-Looking Statements - Minichart
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $48 - Moomoo
NovoCure (NVCR) Q1 2026 Earnings Transcript - The Globe and Mail
NovoCure Limited (NVCR) Reports Strong Q1 2026 Results and FDA A - GuruFocus
Novocure (NVCR) Shares Jump 22% on Strong Q1 Revenue and Raised Outlook - GuruFocus
NovoCure (NASDAQ:NVCR) Shares Gap UpShould You Buy? - MarketBeat
NovoCure: Q1 Earnings Snapshot - theheraldreview.com
NVCR Stock Update: Insights on Current Market Trends - GuruFocus
Novocure (NVCR) Reports Strong Q1 Revenue Growth - GuruFocus
Novocure Jumps On Q1 Revenue Growth; Lifts FY26 Revenue Guidance - RTTNews
NovoCure (NVCR) Q1: EPS -0.62 (miss vs -0.51 est.), Revenue $174 - GuruFocus
NovoCure Shares Rise Following Q1 Financial Results - Moomoo
NovoCure Reports Revenue Growth Driven by New Pancreatic Cancer Therapy - HarianBasis.co
NovoCure Q1 Earnings Call Highlights - MarketBeat
NovoCure Limited 2026 Q1ResultsEarnings Call Presentation (NASDAQ:NVCR) 2026-04-30 - Seeking Alpha
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
NovoCure Ltd 1Q 2026: Revenue $174.06M, EPS ($0.62) — 10-Q Summary - TradingView
NovoCure Ltd reports first quarter 2026 earnings performance - Traders Union
Novocure reports Q1 2026 revenue $174.1M, adjusted EBITDA $(0.3)M, net loss $71.1M - TradingView
Novocure (NASDAQ: NVCR) grows Q1 revenue and raises 2026 outlook - Stock Titan
NovoCure (NASDAQ: NVCR) grows Q1 2026 revenue while investing in new cancer indications - Stock Titan
New pancreatic cancer launch helps Novocure reach $174M in Q1 revenue - Stock Titan
Novocure earnings in focus as new pancreatic therapy debuts By Investing.com - Investing.com Nigeria
Novocure earnings in focus as new pancreatic therapy debuts - Investing.com UK
NovoCure (NASDAQ: NVCR) director converts options into 21,500 shares - Stock Titan
3.34%
자본화:
|
볼륨(24시간):